Compass Pathways, Journey Clinical to develop psilocybin treatment delivery model

Compass Pathways plc (Nasdaq: CMPS) entered into a research collaboration agreement this week with Journey Clinical, a U.S.-based psychedelic-assisted psychotherapy platform.

The collaboration deal aims to develop a scalable and practical delivery and health care provider training model for Compass’ COMP360 psilocybin therapy for treatment-resistant depression, pending regulatory approval, according to a news release Monday.

Compass said that the first phase of the collaboration will involve an in-depth information exchange on the COMP360 psilocybin treatment delivery model. The two companies will work together to gain insights into the patient care experience, depression patient pathways, and care reimbursement processes.

The two companies will also explore more innovative care pathways for TRD patients and conduct research into therapist training, support, and education.

Journey Clinical brings to the table a network of more than 2,000 therapists, an in-house model of therapist peer support and mentorship, and partnerships with leading therapist training providers. The company has built an infrastructure to support broad access to new psychedelic treatments for mental health conditions.

“This collaboration with Compass is closely aligned with Journey Clinical’s aim to support the millions of people in the U.S. living with mental illness to access psychedelic treatments safely and effectively,” Journey Clinical CEO Jonathan Sabbagh said in a statement.

“Compass is forming a comprehensive and diverse network of research collaborations to inform how COMP360 psilocybin treatment can be best integrated into the U.S. health system,” said Kabir Nath, CEO of Compass Pathways. Previous collaborations include agreements with Greenbrook TMS and Hackensack Meridian Health.